Ary K, Róna K, Renczes G, Gachályi B, Riesz T, Grézal G, Klebovich I
Haynal Imre Egészségtudományi Egyetem, I Belgyógyászati Klinika, Klinikai Farmakológiai Részleg, Budapest.
Acta Pharm Hung. 1997 Mar-May;67(2-3):59-63.
Three doses were administered to the rats during the pharmacokinetic study of nerisopam and the plasma concentrations of nerisopam and its N-acetyl metabolite were determined parallelly by means of validated SPE-HPLC method developed by the authors. The pharmacokinetics of nerisopam could be described by a two-compartment open model in rats, it was absorbed rapidly and could be measured in plasma for about 8 hours. The peak plasma concentration of the N-acetyl metabolite was reached rapidly a little bit later than that of the parent compound, similarly to the human plasma, and it could be measured for about 12 hours. The pharmacokinetics of N-acetyl metabolite could be described by an one-compartment open model. The fast appearance of the metabolite and the Cmax and AUC 0-infinity values higher than those of nerisopam refer to an intensive "first-pass" metabolism. The AUC-dose curves indicate that supposingly the mechanism transforming the N-acetyl metabolites are not as fast as the acetylation.
在奈立泮的药代动力学研究期间,给大鼠给予了三剂药物,并通过作者开发的经过验证的固相萃取-高效液相色谱法平行测定了奈立泮及其N-乙酰代谢物的血浆浓度。奈立泮的药代动力学在大鼠中可用二室开放模型描述,它吸收迅速,在血浆中可检测约8小时。N-乙酰代谢物的血浆峰浓度比母体化合物稍晚迅速达到,与人体血浆情况类似,并且可检测约12小时。N-乙酰代谢物的药代动力学可用一室开放模型描述。代谢物的快速出现以及其Cmax和AUC 0至无穷大值高于奈立泮的值表明存在强烈的“首过”代谢。AUC-剂量曲线表明,推测将N-乙酰代谢物转化的机制不如乙酰化那么快。